Ra Pharmaceuticals (RARX) Given Media Impact Score of 0.02

Share on StockTwits

News articles about Ra Pharmaceuticals (NASDAQ:RARX) have trended somewhat positive on Wednesday, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ra Pharmaceuticals earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.1659737203487 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Ra Pharmaceuticals traded down $0.42, hitting $11.06, during mid-day trading on Wednesday, MarketBeat reports. The company had a trading volume of 16,915 shares, compared to its average volume of 331,050. Ra Pharmaceuticals has a 12 month low of $4.78 and a 12 month high of $17.90. The company has a market capitalization of $338.69 million, a price-to-earnings ratio of -4.59 and a beta of 1.75.

Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Wednesday, May 9th. The company reported ($0.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.05). equities analysts expect that Ra Pharmaceuticals will post -2.35 EPS for the current fiscal year.

RARX has been the topic of several research reports. Raymond James initiated coverage on Ra Pharmaceuticals in a research report on Thursday, June 28th. They set an “outperform” rating and a $18.00 price target on the stock. ValuEngine upgraded Ra Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, July 6th. SunTrust Banks restated a “buy” rating on shares of Ra Pharmaceuticals in a research report on Thursday, March 15th. BidaskClub upgraded Ra Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 16th. Finally, BMO Capital Markets dropped their price target on Ra Pharmaceuticals from $34.00 to $31.00 and set an “outperform” rating on the stock in a research report on Thursday, March 15th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $19.25.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Insider Buying and Selling by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply